Article and Video CATEGORIES

Cancer Journey

Search By

Assistant Professor of Medicine, Harvard Medical School

Thoracic Oncologist, Internal Medicine/Medical Oncology, Massachusetts General Hospital

Dana Farber/Harvard Cancer Center

Lung Cancer OncTalk 2024
AlexandraGBeneke
The 2024 Lung Cancer OncTalk was a live, virtual, interactive patient education event presented in December 2024 and led by Dr. Ibiayi Dagogo-Jack. It included presentations and panel discussions covering general subjects relevant to lung cancer and treatment options and an opportunity to speak with the experts in a Q&A session. Speakers included top medical professionals presenting patient-focused discussions to educate the patient and caregiver communities to become advocates for their own health and well-being.
Author
Ibiayi Dagogo-Jack, MD, Guest Faculty
Image
Lung Cancer OncTalk 2024

The 2024 Lung Cancer OncTalk was a live, virtual, interactive patient education event presented in December 2024, moderated by Dr. Ibiayi Dagogo-Jack, Assistant Professor of Medicine at Harvard Medical School and a Medical Oncologist at Massachusetts General Hospital, and joined by speakers: Dr. Misty Shields, Indiana University School of Medicine, Dr. Alissa Cooper, Memorial Sloan Kettering Cancer Center, Dr. Angel Qin, University of Michigan Rogel Cancer Center, and Dr. Julia Rotow, Harvard Medical School. 

Topics include:

- Small Cell Lung Cancer

- Antibody Drug Conjugates (ADCs)

- Combo Therapies for EGFR

- Targeted Therapies in Non-Metastatic Lung Cancer

To watch the complete playlist, click here.

To download video transcripts click here.

A huge thank you to our sponsors! #astrazeneca #daiichisankyo #regeneron #takedaoncology

 

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Online Community

A Brief Tornado.  I love the analogy Dr. Antonoff gave us to describe her presentation.  I felt it earlier too and am looking forward to going back for deeper dive.

Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".

While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".  

I hope any...

My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Recent Comments

JOIN THE CONVERSATION
My understanding of ADCs is…
By JanineT GRACE … on
Right patient, right time,…
By JanineT GRACE … on
A Brief Tornado.  I love the…
By JanineT GRACE … on
Biomarkers
By JanineT GRACE … on